Author

Lisa Eide

Observed name: L. Eide

Institution: aTyr Pharma (United States)

Observed institution: aTyr Pharma (United States)

ORCID: 0009-0001-6832-930X

Observed ORCID: 0009-0001-6832-930X

OpenAlex ID: A5049058473

Inhibition of VEGF binding to neuropilin-2 enhances chemosensitivity and inhibits metastasis in triple-negative breast cancer

2023 · Zhiwen Xu, Hira Lal Goel, et al. · Science Translational Medicine · 49

A human histidyl-tRNA synthetase splice variant therapeutic targets NRP2 to resolve lung inflammation and fibrosis

2025 · Leslie A. Nangle, Zhiwen Xu, et al. · Science Translational Medicine · 16

ATYR1923 Modulates the Inflammatory Response in Experimental Models of Interstitial Lung Disease

2019 · C. Burkart, M. Seikkula, et al. · American Journal of Respiratory and Critical Care Medicine · 5

Abstract 1758: Resistance to cancer therapy via upregulation of the NRP2/VEGF-C axis can be neutralized by ATYR2810

2023 · Alison Barber, Zhiwen Xu, et al. · Cancer Research

Abstract LB085: ATYR2810, a fully humanized monoclonal antibody targeting the VEGF-NRP2 pathway sensitizes highly aggressive and chemoresistant TNBC subtypes to chemotherapy

2022 · Zhiwen Xu, Alison Barber, et al. · Cancer Research

Works count: 5

Citation count: 70

H-index: 3

I10-index: 2